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Abstract
Background: Systemic lupus erythematosus (SLE) is a heterogeneous systemic autoimmune condition for which
there are limited licensed therapies. Clinical trial design is challenging in SLE due at least in part to imperfect
outcome measures. Improved understanding of how disease activity changes over time could inform future trial
design. The aim of this study was to determine whether distinct trajectories of disease activity over time occur in
patients with active SLE within a clinical trial setting and to identify factors associated with these trajectories.
Methods: Latent class trajectory models were fitted to a clinical trial dataset of a monoclonal antibody targeting
CD22 (Epratuzumab) in patients with active SLE using the numerical BILAG-2004 score (nBILAG). The baseline
characteristics of patients in each class and changes in prednisolone over time were identified. Exploratory PK-PD
modelling was used to examine cumulative drug exposure in relation to latent class membership.
Results: Five trajectories of disease activity were identified, with 3 principal classes: non-responders (NR), slow
responders (SR) and rapid-responders (RR). In both the SR and RR groups, significant changes in disease activity
were evident within the first 90 days of the trial. The SR and RR patients had significantly higher baseline disease
activity, exposure to epratuzumab and activity in specific BILAG domains, whilst NR had lower steroid use at
baseline and less change in steroid dose early in the trial.
Conclusions: Longitudinal nBILAG scores reveal different trajectories of disease activity and may offer advantages
over fixed endpoints. Corticosteroid use however remains an important confounder in lupus trials and can influence
early response. Changes in disease activity and steroid dose early in the trial were associated with the overall
disease activity trajectory, supporting the feasibility of performing adaptive trial designs in SLE.
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Background
Systemic lupus erythematosus (SLE) is a systemic in-
flammatory autoimmune condition with few licensed
treatments. A number of promising agents have failed to
show efficacy in phase 3 randomised placebo-controlled
trials [1]. These failures are likely multifactorial but may
be due, at least in part, to the clinical and serological
heterogeneity of SLE and the choice of end-points [2, 3].
Stratified or personalised approaches to treatment is
therefore essential for future drug development and for
the clinical care of this patient group. Biomarkers that
predict response or adverse events are an important un-
met need in SLE [1].
In lupus trials, the choice of outcome measure is crit-
ical. Measures need to be sensitive to changes in clinical
disease activity whilst capturing the breadth of disease
manifestations [3]. Composite measures such as the SLE
responder index (SRI-4) which comprise objective indi-
ces (for example the SLEDAI-2K) along with more sub-
jective measures (e.g. physician global scores) are
currently favoured [4]. Whilst the SRI-4 has been used
in a number of lupus trials [5, 6], there is evidence that a
BILAG-based outcome might be preferable to one based
on the SLEDAI score. In the TULIP-1 study of anifrolu-
mab, a greater difference between active drug and pla-
cebo was observed using the BILAG-based Combined
Lupus Assessment (BICLA) than with the SRI-4 [7].
In other conditions, including rheumatoid arthritis
(RA), latent class models have identified trajectories of
disease activity. This approach offers the opportunity to
identify unobserved groups of patients (latent classes)
who display similar changes in disease activity over time.
In RA, latent class models have been applied to both
clinical trial data [8] and observational cohorts [9–12]. A
number of these studies have identified 3 main classes
with respect to disease activity; typically, a group that
improves rapidly, one that shows little or no improve-
ment and a group that either improves slowly or has an
intermediate response [8, 11, 12].
The aim of this study was to identify whether SLE pa-
tients follow distinct disease activity trajectories within a




We used data from the 2 multicentre double-blind ran-
domised placebo-controlled trials of epratuzumab (EM-
BODY™-1 and EMBODY™-2) in patients with active SLE
[13]. Our dataset comprised 1202/1584 (75%) of the
total cohort and were provided to the MASTERPLANS
Consortium by UCB Biopharma SRL, Brussels. Data
from the screening visit (up to 14 days prior to random-
isation) to the last study visit were included. All patients
were required to fulfil the ACR Classification Criteria for
SLE and have positive antinuclear antibodies and/or
dsDNA antibodies at baseline. Patients with severe active
renal or neurological disease were excluded. Patients
were randomised to epratuzumab (600 mg weekly or
1200 mg alternate weeks) or placebo in a 1:1:1 ratio in
addition to standard of care. Infusions were adminis-
tered over the first 4 weeks of a 3-month dosing cycle
(thus 4 dosing cycles over 48 weeks). Stable doses of im-
munosuppressant or anti-malarial medication were
maintained; dose changes resulted in withdrawal from
the study. All patients were required to be taking 5-
60mg prednisolone daily (or equivalent) at baseline.
Dose increases of up to 25% were permitted from weeks
0–8, with tapering encouraged at a rate of 5mg every 2
weeks aiming for ≤7.5mg day. Follow-up-visits were con-
ducted every 4 weeks until 4 weeks after the end of dos-
ing [13].
Measurement of disease activity
Disease activity was measured using the British Isles Lupus
Assessment Group 2004 (BILAG-2004) [14] and SLE Disease
Activity Index 2000 (SLEDAI-2K) [15] indices.
In line with the MASTERPLANS Consortium, which
uses BILAG-based analyses across the Consortium data-
sets, we defined major clinical response (MCR) and im-
provement at 12 months. MCR was defined as a
reduction in all BILAG-2004 index A and B scores to C
scores, reduction in steroid dose to ≤ 7.5mg daily and a
SLEDAI-2K score of ≤ 4. Improvement was defined as
reduction in BILAG-2004 score to no more than one B
score with no new domains involved, no increase in ste-
roids or SLEDAI-2K score from baseline.
For trajectory modelling the BILAG-2004 numerical
score (nBILAG) was used. The A-E scores of the BILAG-
2004 index are converted to numerical values across all 9
domains such that A=12, B=8, C=1, D/E=0 [16].
Development of latent class mixture models
Latent class mixture models (LCMMs) were used to in-
vestigate disease activity trajectories. As it was expected
that repeated measures within individuals would be
highly correlated, mixed effects models with random
intercept were fitted using the “lcmm” function in the
lcmm package for R with nBILAG as the dependent vari-
able. Models of 1–6 latent classes were constructed
using time as linear, quadratic or cubic functions.
Models were compared using the Bayesian Information
Criteria (BIC) and class size, where >2.5% of the popula-
tion was required in each class. Model adequacy was
measured using the average of posterior probability of
assignments [17]. Model development is described in
further detail in in the supplementary methods.
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The characteristics of patients between latent classes
were evaluated using non-parametric tests and multi-
nomial logistic regression models.
Exploratory PK-PD analysis
Exposure to prednisolone and epratuzumab was esti-
mated using a trapezium model as the sum of the area
under the dose-time curve between each time point (see
supplementary methods). The absolute number and rela-
tive % of CD19+ B cells in the PBMC fraction were mea-
sured by flow cytometry as previously described [13].
Results
Patient characteristics
The dataset comprised 1202 patients with a total of
12,952 study visits. The median (IQR) duration of
follow-up within the study was 350 (247,352) days from
screening to final visit. Age was provided in 3 bands: <
35 years (29.0%), 35–55 years (55.2%) and >55 years
(15.8%); ethnicity data was not available. At baseline,
93.9% of patients were receiving oral prednisolone with
a median dose of 10 (5, 15) mg/day. The median nBI-
LAG score at baseline was 20 (16, 24) and active disease
(defined as a BILAG A or B score) was most frequently
present in the mucocutaneous (82.4%) or musculoskel-
etal (93.7%) domains (Table 1).
Disease activity at baseline and 12 months in the whole
cohort
There was no difference in response rates at 12 months
using either MCR or improvement definitions between
patients receiving epratuzumab or placebo (see supple-
mentary table S1).
Patients with MCR or improvement in the whole co-
hort (both active treatment and/or standard of care)
were older, with lower baseline nBILAG scores, and
lower baseline prednisolone doses (p<0.001 for each). At
baseline, patients with MCR were less likely to have
positive anti-dsDNA antibodies (p=0.011) or low C3/C4
complement (p<0.001, p=0.006), and had higher serum
creatinine concentrations (<0.001). Patients with im-
provement had reduced frequency of low C3 levels (p<
0.001) and were less likely to have anti-RNP antibodies
(p=0.043). In a sensitivity analysis of patients who re-
ceived standard of care alone, lower baseline nBILAG,
lower prednisolone dose, normal C3 and normal C4
(MCR only) were statistically significant predictors of re-
sponse (see supplementary table S1).
Trajectories of numerical BILAG score over time: latent
class mixed models
Latent class mixed models of disease activity over time
were constructed for all patients. Numerical BILAG was
selected in preference to SLEDAI-2K score as it showed
increased sensitivity to change over the first 90 days (see
supplementary figure S1). Based on both the BIC and
the group sizes, a 5-group cubic spline model was se-
lected, with groups defined by non-responders (NR,
33.9%), slow-responders (SR, 20.7%), rapid responders
(RR, 36.7%), high disease activity (HDA, 3.91%) and flare
(F, 4.74%) (Fig. 1). The median nBILAG score at baseline
and last study visit was 17 (16, 21) and 13 (9, 17) in the
NR group, 20 (16, 25) and 3 (1, 10) in the RR group and
20 (16, 25) and 3 (1, 10) in the SR group respectively.
The median reduction in nBILAG from baseline to 6
months was 15 (11.5, 19) in the RR group, 15 (12, 19) in
the SR group and 5.5 (0, 8) in the NR group (p<0.001).
In sensitivity analyses, 5-group cubic spline LCMMs
were constructed to include only patients receiving (i)
epratuzumab or (ii) placebo. The trajectories of
epratuzumab-treated patients were similar to those ob-
served in the whole cohort. The placebo-treated model
showed different trajectories with an absent HDA group
and two flare groups (less severe, earlier flare and a more
severe, later flare) (Fig. 2). A comparison between the la-
tent classes and MCR/improvement at 12 months is
shown in Fig. 3 and in the supplementary table S2. The
proportion of patients meeting MCR or improvement at
12 months was similar between the RR and SR groups.
There was not complete overlap between the trajectories
and the MCR/Improvement outcomes in part due a
number of patients in each trajectory failing to fulfil the
additional SLEDAI and steroid reduction criteria for the
landmark end-points (supplementary table S3). The tra-
jectories of SLEDAI score over time, for each of the 5 la-
tent classes, demonstrated similar trajectories (see
supplementary figure S2).
As the HDA and F groups each comprise <5% of the
population, they were excluded from further analyses.
Characteristics of responder and non-responder latent
classes in the whole cohort
Patients in the NR, SR and RR latent classes were not
significantly different in terms of age, gender or disease
duration (Table 2). Although the SLEDAI-2K score was
similar between groups, NR had a lower baseline nBI-
LAG score compared to the other 2 groups (17 [16, 21]
vs. 20 [16, 25] and 20 [16, 25] respectively, p<0.001).
NRs were less likely to have activity in the constitutional,
musculoskeletal or cardiorespiratory systems compared
to RR and SR (see Table 3). Whilst there were no differ-
ences in the drop-out rate due to adverse events (NR
5.9%, SR 5.6%, RR 6.6%, p=0.858), drop-outs due to lack
of efficacy were significantly higher in the NR group (NR
20.6%, SR 7.6%, RR 8.4%, p<0.001).
Multinomial logistic regression models were con-
structed to identify baseline variables associated with be-
ing in the RR or SR class, compared with the NR class
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(Table 3). Higher baseline nBILAG score and steroid
dose was associated with being in both RR and SR latent
classes. Similarly, active constitutional and musculoskel-
etal domains were associated with both classes, whilst an
active cardiorespiratory domain was only significantly as-
sociated with the RR latent class. Receiving epratuzumab
(1200mg QoW) was associated with being in the RR
group only (relative risk ratio, RRR 1394 [1.003, 1.936]).
There were no baseline serological biomarkers which
predicted latent class membership. Similarly there were
no differences in the change in anti-dsDNA, C3 or C4
levels from baseline to 3 months, 6 months or study end
Table 1 Baseline demographic variables of the cohort analysed
Characteristics Whole cohort (n=1202) Epratuzumab plus standard of care (n=792) Standard of care only (n=410)
Age group (years)
<35 348 (29.0%) 224 (28.3%) 124 (30.2%)
35–55 664 (55.2%) 436 (55.1%) 228 (55.6%)
>55 190 (15.8%) 132 (16.7%) 58 (14.2%)
Female 1131 (94.1%) 739 (93.3%) 392 (95.6%)
Disease duration (years) 5.58 (1.92, 12.7) 5.75 (1.92, 12.7) 5.46 (1.83, 11.9)
ACR/SLICC-DI 0 (0, 2) 0 (0, 2) 0 (0, 2)
SLEDAI-2K 10 (8, 12) 10 (8, 12) 10 (8, 12)
nBILAG-2004 score median (IQR) 20 (16, 24) 20 (16, 24) 20 (16, 24)
BILAG-2004 A or B system score
Constitutional 117 (9.73%) 74 (9.34%) 43 (10.5%)
Mucocutaneous 990 (82.4%) 653 (82.5%) 337 (82.2%)
Neuropsychiatric 50 (4.16%) 36 (4.55%) 14 (3.41%)
Musculoskeletal 1126 (93.7%) 741 (93.6%) 385 (93.9%)
Cardiorespiratory 132 (11.0%) 89 (11.2%) 43 (10.5%)
Gastrointestinal 23 (1.91%) 13 (1.64%) 10 (2.44%)
Ophthalmological 15 (1.25%) 10 (1.26%) 5 (1.22%)
Renal 91 (7.57%) 62 (7.83%) 29 (7.07%)
Haematological 12 (1.00%) 9 (1.14%) 3 (0.73%)
Serology
Anti-Ro 571 (48.2%) 373 (47.8%) 198 (49.0%)
Anti-RNP 353 (29.8%) 235 (30.1%) 118 (29.2%)
Anti-dsDNA 334 (28.2%) 211 (27.1%) 123 (30.4%)
Anti-Smith (Sm) 311 (27.3%) 204 (26.2%) 107 (26.5%)
Low C3 level 395 (33.4%) 257 (33.0%) 138 (34.2%)
Low C4 level 482 (40.8%) 320 (41.1%) 162 (40.1%)
Baseline steroid use 1129 (93.9%) 757 (95.6%) 372 (90.7%)
Baseline steroid dose (mg/day) 10 (5, 15) 10 (5, 15) 10 (5, 15)
Concomitant therapy
Anti-malarial 884 (73.5%) 595 (75.1%) 289 (70.5%)
Methotrexate 251 (20.9%) 165 (20.8%) 86 (21.0%)
Leflunomide 37 (3.08%) 37 (3.08%) 37 (3.08%)
Azathioprine 321 (26.7%) 321 (26.7%) 321 (26.7%)
Mycophenolate mofetil 143 (11.9%) 88 (11.1%) 55 (13.4%)
Drop out from trial 385 (32.0%) 259 (32.7%) 126 (30.7%)
Withdrawal (lack of efficacy) 174 (14.5%) 115 (14.5%) 59 (14.4%)
Withdrawal (adverse events) 78 (6.49%) 52 (6.57%) 26 (6.34%)
Values are n (%) or median (IQR) as appropriate
Reynolds et al. Arthritis Research & Therapy          (2021) 23:203 Page 4 of 12
between latent classes, except in the subgroup of pa-
tients with high anti-dsDNA at baseline (see supplemen-
tary table S4).
In multivariable models adjusted for age group, gender
and disease duration, these associations all remained sig-
nificant (Table 4). In further exploratory analyses, the
RR and SR latent classes were combined into a single re-
sponder group (see supplementary table S5 and S6).
Relationship between early changes in disease activity
and latent class membership
The changes in nBILAG score between baseline and
1, 2 and 3 month time points, and the final study
visit, were compared between the RR, SR and NR
latent classes (Table 5 and supplementary figure S3).
At 1 month, the median change in nBILAG was simi-
lar between NR and SR; at 2 and 3 months, clear dif-
ferences were observed between the 3 latent classes
By the final study visit, there was no difference in
nBILAG reduction between RR and SR classes but
both of these had around a 2-fold greater reduction
in nBILAG compared to the NR class. In the NR tra-
jectory, only 29/408 (7.11%), 32/408 (7.84%) and 26/
408 (6.37%) had a reduction in nBILAG scores of <10
at 1, 2 and 3 months respectively. The sensitivity and
specificity of a change in nBILAG score of <10 to
identify patients in the NR latent class was 93.6% and
65.5% respectively.
Fig. 1 The 5-class cubic LCMM for the whole cohort. A The figure shows smoothed curves for each of the 5 classes over time. The trajectories
are smoothed using a generalised additive model. B The 5 panels show the “spaghetti plots” for each of the 5 classes where each line represents
a single patient. SR slow responder, HDA high disease activity, NR non-responder, RR rapid responder, F flare
Fig. 2 Latent class models according to treatment received. The trajectories in a 5-class model are shown for the whole cohort, those patients
receiving epratuzumab (at either dose) or patients receiving placebo respectively. In the epratuzumab group, there are trajectories similar to the
whole cohort. In the placebo group, the yellow group flares earlier than in the whole cohort. The HDA group is not observed in the placebo
model, but instead a second flare group with a later flare is seen (blue). The 3 trajectories of NR, SR and RR are similar between cohorts, although
the RR and SR show greater separation in the placebo group.
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Steroid exposure over time and latent classes
Patients in the NR group had slightly lower baseline pred-
nisolone doses than either SR or RR (see Table 2).
Amongst patients who completed the trial, those in the
RR group had more rapid tapering although the total re-
duction was only 1.25 [0, 7.5] mg/day (supplementary fig-
ure S4). The median cumulative steroid exposure in the
first 90 days was higher in the RR and SR groups (965
[495, 1545] and 980 [500, 1485] mg days) vs. the NR
group (761 [500, 1185] mg days) (p=0.0391). The NR
group did not show any early reduction in their steroid
dose whilst the RR patients were more likely to have re-
duced their steroid dose at 2 and 3 months; p<0.001 for
both (Table 4 and supplementary figure S4). By the last
study visit, steroid reduction was greater in the RR group
compared to either SR or NR. In a multivariable logistic
regression model (comprising age, gender, disease dur-
ation, number of days in the trial, and receiving epratuzu-
mab), steroid exposure in the first 90 days (g days)
remained independently associated with being in the RR
(RRR 1.46 [1.206, 1.789], p<0.001] or SR latent classes
(1.34 [1.706, 1.688], p=0.009) whilst receiving epratuzu-
mab was not (RRR 1.26 [0.926, 1.703] and 1.27 [0890,
1.011] for RR and SR respectively compared to placebo).
Exploratory PK-PD analysis
The maximum drug concentration (Cmax) was higher
with the 1200mg QoW regimen compared to the
600mg QW regimen (median [IQR] 61.5 [51.6, 71.0]
vs. 43.7 [36.3, 52.1] 103 units/ml, p<0.0001). Con-
versely, the exposure (AUC) was lower in the 1200mg
QoW regimen compared to 600mg QW (45.0 [29.4,
58.0] vs. 58.3 [39.4, 71.4] 106unit days/ml, p<0.0001).
As the AUC is dependent on the number of days in
the trial, the average exposure/day was determined
using AUC/number of days in the trial (see supple-
mentary figure S5).
A higher average exposure (103 unit days/ml) was as-
sociated with being in the RR or SR class compared to
NR after adjustment for age, gender, disease duration,
baseline steroid dose and treatment group: relative risk
ratio 1.004 (1.001, 1.007) (p<=0.016) for RR and 1.005
(1.002, 1.009) (p=0.005) for SR. In a sensitivity analysis
using the LCMM of only those patients receiving epratu-
zumab, this observation remained statistically significant:
RRR 1.004 (1.0004, 1.007), p=0.025, for RR and 1.005
(1.001, 1.009) for SR compared to NR. There was no sig-
nificant association between Cmax and responder class
(not shown).
There was no significant difference in baseline abso-
lute and % CD19+ cells in the RR group compared to
the SR or NR groups: 105 (41, 225) vs. 90 (34, 175) and
89 (38, 182), p=0.108, for absolute counts and 9 (5, 14)
vs. 8 (4, 13) and 8(4, 13), p=0.169 for % counts.
Treatment with epratuzumab reduced CD19+ counts
(Fig. 4). Using a population-averaged linear model ad-
justed for age group, gender disease duration and base-
line nBILAG score, both epratuzumab doses, were
associated with a reduction in CD19+ counts (β −37.6 [−
53.1, −22.1], p<0.0001, for epratuzumab 600mg QW and
β − 38.1 [− 53.7, − 22.5], p<0.001, for epratuzumab
1200mg QoW) compared to placebo. There was no sta-
tistically significant reduction in absolute CD19+ counts
at last study visit in RR (− 19 [− 88, 7.5]) compared to
SR (− 16.5 [− 74.5, 8]) or NR (− 11 [− 61, 7]), p=0.139.
Discussion
This study is the first to apply latent trajectory modelling
to patients with SLE in a clinical trial setting. Patients
with active SLE displayed discrete trajectories of disease
Fig. 3 Comparison between latent class membership and response at 12 months. The bars show the number of patients in each of the 5 latent
classes and major clinical response (A) or improvement (B) at 12 months. The number above the bar is the % of patients that meet the MCR or
improvement definition in each latent class group. The stricter MCR definition is not met by most of the NR, but also by few of the SR and RR.
The definition of improvement would classify more of the patients in the NR latent class as responders
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activity over time. Although 5 classes were considered to
best fit the data, the majority of patients were in 3 clas-
ses: non-response (NR), rapid response (RR) and slow
response (SR). These separated within the first 90 days
of the trial period with several baseline factors associated
with response/non-response trajectories.











Age group (years) 0.669
<35 119 (29.1%) 72 (28.9%) 117 (26.5%)
35–55 230 (56.4%) 133 (53.4%) 247 (56.0%)
>55 59 (14.5%) 44 (17.7%) 77 (17.5%)
Female 387 (94.9%) 237 (95.2%) 412 (93.4%) 0.542
Disease duration (years) 6.04 (2.17, 13.3) 5.17 (1.92. 12.4) 5.33 (1.75, 12.3) 0.373
ACR/SLICC-DI 0 (0, 2) 0 (0, 2) 0 (0, 2) 0.905
SLEDAI-2K 9.5 (8, 12) 10 (8, 12) 10 (8, 12) 0.394
nBILAG score 17 (16, 21) 20 (16, 25) 20 (16, 25) <0.001
BILAG 2004 A or B score
Constitutional 15 (3.68%) 26 (10.4%) 59 (13.4%) <0.001
Mucocutaneous 335 (82.1%) 212 (85.1%) 362 (82.1%) 0.535
Musculoskeletal 365 (89.5%) 237 (95.2%) 425 (96.4%) <0.001
Cardiorespiratory 25 (6.13%) 25 (10.0%) 63 (14.3%) <0.001
Gastrointestinal 3 (0.74%) 6 (2.41%) 8 (1.81%) 0.203
Ophthalmological 4 (0.98%) 2 (0.8%) 6 (1.36%) 0.766
Haematological 5 (1.23%) 2 (0.80%) 5 (1.13%) 0.875
Serology
Anti-Ro 198 (48.8%) 108 (44.8%) 207 (47.5%) 0.621
Anti-RNP 109 (26.9%) 61 (25.3%) 142 (32.6%) 0.074
Anti-dsDNA 107 (26.3%) 63 (26.1%) 123 (28.3%) 0.759
Anti-dsDNA level* (IU/ml) (n=314) 291 (181, 456) 261 (175, 491) 291 (185, 544) 0.618
Anti-Smith (Sm) 96 (23.7%) 59 (24.5%) 117 (26.8%) 0.548
Low C3 level 129 (32.3%) 78 (32.0%) 143 (32.9%) 0.966
C3 level (g/l) 1.08 (0.84, 1.30) 1.06 (0.85, 1.27) 1.08 (0.83, 1.28) 0.803
Low C4 level 165 (41.3%) 88 (36.1%) 181 (41.6%) 0.320
C4 level (mg/l) 200 (120, 300) 220 (150, 300) 200 (130, 310) 0.591
Epratuzumab (either dose) 252 (61.8%) 170 (68.3%) 300 (68.0%) 0.100
Baseline steroid dose (mg/day) 9.5 (5, 10) 10 (5, 15) 10 (5, 15) 0.0418
Cumulative steroid exposure (mg days) 2247.5 (1532.5, 3500) 2685 (1750, 4062.5) 2360 (1685, 3610) 0.0027
Concomitant therapy
Anti-malarial 279 (72.8%) 187 (75.1%) 327 (74.2%) 0.795
Methotrexate 84 (20.6%) 55 (22.1%) 94 (21.3%) 0.899
Leflunomide 9 (2.21%) 6 (2.41%) 17 (3.85%) 0.312
Azathioprine 116 (28.4%) 73 (29.3%) 104 (23.8%) 0.158
Mycophenolate mofetil 44 (10.8%) 29 (11.7%) 54 (12.4%) 0.801
Withdrawal (lack of efficacy) 84 (20.6%) 19 (7.63%) 37 (8.93%) <0.001
Withdrawal (adverse events) 24 (5.88%) 14 (5.62%) 29 (6.58%) 0.853
Values are n (%) or median (IQR) as appropriate
*Only in patients with high-dsDNA
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Disease activity trajectories have been observed in pa-
tients with RA in both clinical trials [8] and observa-
tional cohorts [8, 11, 12]. The number and shape of
latent class trajectories is dependent on the data and
outcome measures used [9]. It is essential therefore that
the outcome measure is sensitive to change over time.
The nBILAG score has a wider range of values than
SLEDAI-2K and can detect partial or incomplete re-
sponses. Relative to the NR, significant changes in nBI-
LAG occurred as early as 1 month in the RR group and
2 months in the SR group. In the RR group, no further
change in nBILAG was observed between 3 months and
the last visit. This suggests that changes in disease
activity typically occur early in the course of clinical tri-
als. These observations may be specific to epratuzumab,
and/or the organ system involved; for example, remis-
sion may take >12 months in patients with lupus neph-
ritis [18, 19] resulting in different trajectories in that
patient group. These data further support the use of the
BILAG-2004 index, and BILAG-based outcome mea-
sures, in lupus clinical trials. Furthermore, if our obser-
vations are replicated in other cohorts, this would enable
the design of adaptive trials in SLE. Our data suggests
that a non-response trajectory could be identified as
early as 3 months, allowing these patients to be re-
randomised to the next mode of action agent, greatly
Table 3 Multinomial logistic regression models of baseline variables associated with being in either the RR or SR latent class
compared to NR using data from the whole cohort
Slow responder (SR) Rapid responder (RR)
RRR 95% CI p RRR 95% CI p
Age group
<35 Ref Ref Ref Ref Ref Ref
35–55 0.956 0.665, 1.373 0.806 1.092 0.799, 1.492 0.579
>55 1.232 0.757, 2.001 0.401 0.137 0.868, 2.029 0.191
Female 1.071 0.518, 2.212 0.825 0.771 0.432, 1.137 0.378
Disease duration 0.988 0.969, 1.008 0.255 0.991 0.975, 1.008 0.312
Disease activity
Baseline nBILAG-2004 score 1.092 1.061, 1.124 <0.001 1.083 1.055, 1.112 <0.001
Baseline SLEDAI score 1.035 0.991, 1.080 0.122 1.023 0.985, 1.063 0.233
BILAG A or B constitutional 3.054 1.585, 5.889 0.001 4.047 2.257, 7.256 <0.001
BILAG A or B musculoskeletal 2.326 1.202, 4.503 0.012 3.129 1.733, 5.649 <0.001
BILAG A or B cardiorespiratory 1.710 0.959, 3.049 0.069 2.552 1.572, 4.145 <0.001
Medication
Study arm
Placebo Ref Ref Ref Ref Ref Ref
E-mab 1200mg QoW 1.300 0.881, 1.920 0.187 1.394 1.003, 1.936 0.047
E-mab 600mg QW 1.362 0.929, 1.997 0.113 1.244 0.895, 1.727 0.194
Epratuzumab (either dose) 1.332 0.954, 1.859 0.092 1.317 0.993, 1.747 0.056
Baseline steroid dose (mg/day) 1.022 1.003, 1.041 0.022 1.028 1.011, 1.045 0.001
Serology
Anti-Ro 0.853 0.619, 1.175 0.330 0.950 0.724. 0.124 0.708
Anti-RNP 0.923 0.641, 1.329 0.668 1.316 0.977, 1.771 0.070
Anti-dsDNA 0.992 0.691, 1.424 0.967 1.105 0.815, 1.497 0.518
Anti-dsDNA titre* IU/ml
(n=314)
1.000 0.999, 1.002 0.776 1.000 1.000, 1.002 0.246
Anti-Smith (Sm) 1.046 0.721, 1.519 0.810 1.184 0.867. 1.617 0.288
Low C3 level 0.978 0.701, 1.389 0.941 1.029 0.770, 1.375 0.848
C3 level (g/l) 0.806 0.493, 1.317 0.389 0.951 0.628, 1.441 0.814
Low C4 level 0.803 0.578 1.116 0.192 1.015 0.770, 1.337 0.916
C4 level (mg/l) 1.001 0.999, 1.002 0.438 1.001 0.999, 1.001 0.920
*Only in patients with high anti-dsDNA
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enhancing the efficiency and cost-effectiveness of SLE
trials.
The latent class approach categorised patients differ-
ently compared to fixed outcome measures at 12
months. Using our Consortium’s response end-points of
MCR or improvement, there was no association between
receiving active drug and improvement/MCR at 12
months, consistent with the phase 3 epratuzumab (EM-
BODY) trials [13]. In contrast one of the dosing regi-
mens was associated with being in the RR latent class.
This supports the findings of the phase 2 study, and the
post hoc analysis of EMBODY (which demonstrated im-
provement in patients with concomitant Sjogren’s syn-
drome) [20, 21]. However, our results confirm that
baseline anti-Ro antibody status alone cannot identify re-
sponders. These data need to be interpreted in the con-
text of both phase 3 RCTs not meeting their primary
endpoint (BICLA response). Importantly, there was only
a modest association between the latent class groups
and the MCR/improvement endpoints. This likely re-
flects that the latent class models are based on changes
in BILAG score alone, whilst the composite endpoints
included changes SLEDAI score and in daily steroid
dose. Patients in RR or SR classes were equally likely to
meet each of the criteria (based on BILAG, SLEDAI and
steroid) but not necessarily all three. In addition even
the usual BILAG-based and SLEDAI-based composite
endpoints do not always show complete agreement, as
observed in the phase 3 trials of anifrolumab [7, 22].
Exploratory PK analyses identified that average drug
exposure, but not maximum drug level, was associated
with response. This supports the observation in the
APRIL-SLE study that exposure to atacicept (determined
using average trough concentrations) was associated
with reduced flare rate [23]. Within our study, there was
a marked variation in drug exposure between partici-
pants. Optimising drug exposure, where the dose of drug
is increased until a target exposure is reached, could be
included in future adaptive lupus trials to maximise
treatment responses. Whilst our study provides some
evidence that epratuzumab may be efficacious in the
treatment of SLE, the confounding effects of steroids
were significant and further analyses of drug exposure
are warranted in clinical trial datasets.
Steroid use remains an important concern in SLE tri-
als. The EMBODY studies allowed generous daily pred-
nisolone doses (up to 60mg a day, with increases of up
to 25% during the first 4 weeks). Steroid doses remained
Table 4 Multinomial logistic regression models of baseline variables associated with being in a SR or RR latent class adjusted for
age, gender, disease duration and time in the study
Slow responder (SR) Rapid responder (RR)
OR 95% CI P OR 95% CI P
Baseline nBILAG-2004 score 1.100 1.067, 1.132 <0.001 1.089 1.060 1.119 <0.001
BILAG A or B constitutional 3.072 1.576, 5.990 0.001 4.196 2.323, 7.580 <0.001
BILAG A or B musculoskeletal 2.252 1.150, 4,410 0.018 3.073 1.692, 5.580 <0.001
BILAG A or B cardiorespiratory 1.607 0.894, 2.887 0.113 2.461 1.510, 4.011 <0.001
Medication
Study arm
Placebo Ref Ref Ref Ref Ref Ref
E-mab 1200mg QoW 1.344 0.904, 2.000 0.144 1.417 1.017, 1.975 0.039
E-mab 600mg QW 1.379 0.934, 1.036 0.106 1.237 0.887, 1.726 0.209
Baseline steroid dose (mg/day) 1.028 1.008, 1.049 0.005 1.033 1.016, 1.051 <0.001
Table 5 Changes in numerical BILAG-2004 index score between baseline and 1, 2 and 3 months by latent class membership
Latent class 1 month 2 months 3 months Last visit
Reduction in nBILAG score from baseline (median, IQR)
NR 0 (0, 7) 2 (0, 7) 3 (0, 7) 7 (1, 11)
SR 0 (0, 5) 7 (1, 10) 11 (7, 14) 15 (11, 19)
RR 11.5 (7, 14) 15 (12, 19) 15 (12, 19) 15 (11, 20)
Number (%) of patients with reduction in daily prednisolone dose
NR 19 (4.7%) 40 (9.8%) 42 (10.3%) 93 (22.8%)
SR 13 (5.2%) 27 (10.8%) 30 (12.1%) 87 (34.9%)
RR 31 (7.0%) 82 (18.6%) 95 (21.5%) 182 (41.3%)
Values are median (IQR)
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relatively static over the trial despite the protocol en-
couraging steroid reduction [13]. There may therefore
be intrinsic differences between centres in how aggres-
sively steroid reduction was undertaken and more recent
lupus trials have adopted stricter steroid reduction pro-
tocols [22]. Interestingly, both baseline dose and steroid
exposure was lower in the NR group and adjusting for
this eliminated the association between active drug and
response. Accounting for overall steroid exposure, rather
than simply, baseline dose or change in dose, is therefore
important in lupus trials. Early steroid dose reduction, as
observed in the RR group, might also relate to the long-
term response trajectory and form part of a future meas-
ure to identify those patients following a response trajec-
tory within the first 3 months of a trial.
Identifying predictors of response is an important step
towards personalised treatment in SLE. Using fixed out-
comes, older age, lower baseline nBILAG scores, normal
anti-dsDNA antibodies, serum creatinine and complement
levels and lower baseline prednisolone doses were associ-
ated with response at 12 months. However, the majority
of these predictors applied to both active drug and stand-
ard of care groups. The latent class analysis identified that
higher disease activity (notably constitutional, musculo-
skeletal and cardiorespiratory domains), steroid and epra-
tuzumab exposure, but not serological biomarkers were
associated with response classes. This discrepancy may
arise as both high anti-dsDNA and low C3/4 form part of
the SLEDAI-2K score and thus contribute to the defini-
tions of MCR and improvement used in the study. In
addition, the number of patients with high anti-dsDNA
levels was relatively low as the trial excluded patients with
severe active lupus nephritis. Patients with lower baseline
disease activity and normocomplementaemia may be
more likely to respond to standard of care alone, thus re-
ducing the effect size in a trial setting.
Although latent class trajectory modelling remains an ex-
ploratory tool, which can be limited by over-fitting models
to the data, all 5 trajectories were deemed clinically mean-
ingful. A principal disadvantage of the approach used is that
the nBILAG score removes the ability of the BILAG-2004
index to compare between different organ domains. A fur-
ther limitation is that the RR and SR latent classes are based
solely on changes in disease activity, which may not equate
to clinical remission or improvement in patient-reported
outcomes. Our dataset comprised patients with moderate-
severe disease activity within a clinical trial setting. Notably
patients with severe active renal and neurological disease,
or significant haematological abnormalities, were excluded.
The results therefore may not be generalisable to patients
with these manifestations or with a mild flare of disease.
Similarly, there were only a small number of disease flares.
This is not unexpected in a clinical trial setting and analysis
of disease flare in SLE would require a long-term observa-
tional cohort study.
The ability to predict which disease activity trajectory
a patient is likely to follow would allow more efficient
and cost-effective trials. Adaptive trial designs where de-
cisions are based on early changes in disease activity and
steroid doses, rather than specified ‘landmark’ endpoints,
are an attractive option to explore in SLE. Such studies
would ensure that the best use is made of all data col-
lected in trials and that an ‘early fail’ decision could be
made with sufficient confidence to allow reassignment of
patients to an alternative MOA agent. Our results sug-
gest such an approach is feasible and is worthy of further
validation and testing. This approach is likely to be most
suited to early phase trials; however, if validated in other
studies, it may also have a role in later phase trials, espe-
cially those addressing a treatment strategy for SLE.
Conclusion
Distinct trajectories of disease activity over time in pa-
tients with SLE were identified in a clinical trial setting.
Changes in disease activity occurred early within the trial
which may make adaptive trial designs feasible in SLE.
Fig. 4 Change in the number of CD19+ cells over the course of the trial. The absolute number of CD19+ cells fell more quickly in the 600mg
QW treatment group compared to the 1200mg QoW group (A). There was a trend towards a greater reduction in CD19+ cell count in the RR
group compared to the SR group (B). The graphs show LOWESS smoothed curves
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